z-logo
open-access-imgOpen Access
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ‐secretase inhibitor drug responses
Author(s) -
Azzam Diana J.,
Zhao Dekuang,
Sun Jun,
Minn Andy J.,
Ranganathan Prathibha,
DrewsElger Katherine,
Han Xiaoqing,
PiconRuiz Manuel,
Gilbert Candace A.,
Wander Seth A.,
Capobianco Anthony J.,
ElAshry Dorraya,
Slingerland Joyce M.
Publication year - 2013
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.201302558
Subject(s) - miami , breast cancer , cancer , medicine , gerontology , library science , computer science , environmental science , soil science
Increasing evidence suggests that stem‐like cells mediate cancer therapy resistance and metastasis. Breast tumour‐initiating stem cells (T‐ISC) are known to be enriched in CD44 + CD24 neg/low cells. Here, we identify two T‐ISC subsets within this population in triple negative breast cancer (TNBC) lines and dissociated primary breast cancer cultures: CD44 + CD24 low+ subpopulation generates CD44 + CD24 neg progeny with reduced sphere formation and tumourigenicity. CD44 + CD24 low+ populations contain subsets of ALDH1 + and ESA + cells, yield more frequent spheres and/or T‐ISC in limiting dilution assays, preferentially express metastatic gene signatures and show greater motility, invasion and, in the MDA‐MB‐231 model, metastatic potential. CD44 + CD24 low+ but not CD44 + CD24 neg express activated Notch1 intracellular domain (N1‐ICD) and Notch target genes. We show N1‐ICD transactivates SOX2 to increase sphere formation, ALDH1+ and CD44 + CD24 low+ cells. Gamma secretase inhibitors (GSI) reduced sphere formation and xenograft growth from CD44 + CD24 low+ cells, but CD44 + CD24 neg were resistant. While GSI hold promise for targeting T‐ISC, stem cell heterogeneity as observed herein, could limit GSI efficacy. These data suggest a breast T‐ISC hierarchy in which distinct pathways drive developmentally related subpopulations with different anti‐cancer drug responsiveness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here